Table 1.
Patient demographics and clinical characteristics at apremilast initiation (all patients, N = 180)
| Characteristic | Value |
|---|---|
| Gender (N = 180), n (%) | |
| Male | 103 (57.2) |
| Female | 77 (42.8) |
| Age (years) (N = 180), mean (SD) | 59.1 (12.4) |
| BMI (kg/m2) (N = 176), mean (SD) |
176 27.1 (5.1) |
| Time interval from psoriasis diagnosis to apremilast initiation (years) (N = 180), median (IQR) | 8.6 (3.2–22.2) |
| Presence of comorbidities*(N = 180), n (%) | |
| Any | 133 (73.9) |
| Hypertension | 65 (36.1) |
| Psoriatic arthritis | 60 (33.3) |
| Metabolic diseases | 59 (32.8) |
| Chronic infections | 31 (17.2) |
| Malignancies | 26 (14.4) |
N number of patients with non-missing data, n number of patients with characteristic of interest, SD standard deviation, IQR interquartile range, BMI body mass index
*Comorbidities present in ≥ 10% of patients are listed. Metabolic diseases include diabetes, hypercholesterolemia/dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and obesity